Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Lotharius

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The Journal of Biological Chemistry|July 30, 2002
Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell lineJulie Lotharius, Sebastian Barg, Pia Wiekop, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 8, 2005
Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathwayJulie Lotharius, Jeppe Falsig, Johan van Beek, et al.
Antimicrobial Agents and Chemotherapy|November 16, 2011
In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium speciesSergio Wittlin, Eric Ekland, J Carl Craft, et al.
Journal of Neurochemistry|July 24, 2010
HIF prolyl hydroxylase inhibition increases cell viability and potentiates dopamine release in dopaminergic cellsJens Leander Johansen, Thomas Nikolaj Sager, Julie Lotharius, et al.
Toxicology and Applied Pharmacology|August 4, 2009
Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cellsStefan Schildknecht, Dominik Pöltl, Daniel M Nagel, et al.
Drug Design, Development and Therapy|November 21, 2013
In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium modelsSarah Schleiferböck, Christian Scheurer, Masataka Ihara, et al.
Malaria Journal|April 16, 2014
Repositioning: the fast track to new anti-malarial medicines?Julie Lotharius, Francisco Javier Gamo-Benito, Iñigo Angulo-Barturen, et al.
The Lancet. Infectious Diseases|April 2, 2017
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised studyJames S McCarthy, Julie Lotharius, Thomas Rückle, et al.
Science Translational Medicine|July 17, 2015
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malariaMargaret A Phillips, Julie Lotharius, Kennan Marsh, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Journal of Biological Chemistry|July 30, 2002
Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell lineJulie Lotharius, Sebastian Barg, Pia Wiekop, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 8, 2005
Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathwayJulie Lotharius, Jeppe Falsig, Johan van Beek, et al.
Antimicrobial Agents and Chemotherapy|November 16, 2011
In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium speciesSergio Wittlin, Eric Ekland, J Carl Craft, et al.
Journal of Neurochemistry|July 24, 2010
HIF prolyl hydroxylase inhibition increases cell viability and potentiates dopamine release in dopaminergic cellsJens Leander Johansen, Thomas Nikolaj Sager, Julie Lotharius, et al.
Toxicology and Applied Pharmacology|August 4, 2009
Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cellsStefan Schildknecht, Dominik Pöltl, Daniel M Nagel, et al.
Drug Design, Development and Therapy|November 21, 2013
In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium modelsSarah Schleiferböck, Christian Scheurer, Masataka Ihara, et al.
Malaria Journal|April 16, 2014
Repositioning: the fast track to new anti-malarial medicines?Julie Lotharius, Francisco Javier Gamo-Benito, Iñigo Angulo-Barturen, et al.
The Lancet. Infectious Diseases|April 2, 2017
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised studyJames S McCarthy, Julie Lotharius, Thomas Rückle, et al.
Science Translational Medicine|July 17, 2015
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malariaMargaret A Phillips, Julie Lotharius, Kennan Marsh, et al.
Pageof 2